Thousands of patients prescribed semaglutide medications like Ozempic, Wegovy, and Rybelsus have filed product liability lawsuits against manufacturer Novo Nordisk. Plaintiffs allege these diabetes and weight-loss drugs caused non-arteritic anterior ischemic optic neuropathy (NAION), a rare and often permanent condition involving sudden vision loss.
As of late summer 2026, these federal cases are consolidated in MDL No. 3163 in the U.S. District Court for the Eastern District of Pennsylvania under Judge Karen S. Marston. While pretrial fact discovery moves forward with a deadline set for October 2026, no global settlement or claim resolution program has been announced.
In Plain English: The Clinical Takeaway
- The Core Allegation: Lawsuits claim that Novo Nordisk failed to properly warn patients and physicians that semaglutide drugs could trigger NAION, a disruption of blood flow to the optic nerve.
- The Clinical Condition: NAION causes sudden, often irreversible loss of eyesight usually affecting one eye. Medical literature notes that about 15% of patients with NAION eventually experience it in the other eye.
- The Current Legal Status: Active multidistrict litigation (MDL 3163) and a parallel New Jersey state proceeding are ongoing. No settlement funds exist, and no claim submission forms are open to the public.
The Scientific Evidence and Central Legal Arguments
The core scientific debate centers on whether GLP-1 receptor agonists directly contribute to vascular events in the optic nerve. Plaintiffs point to observational research published in JAMA Ophthalmology in July 2024, which suggested an elevated risk of NAION among patients prescribed semaglutide for diabetes or weight management. A subsequent study published in 2025 in the Journal of the American Medical Association reported that patients taking Ozempic showed roughly 1.8 times the risk of experiencing vision loss from NAION compared to individuals prescribed alternative diabetes medications.
Complementing these findings, the World Health Organization issued an advisory in June 2025 warning that semaglutide therapies may rarely cause NAION. The legal teams for the plaintiffs argue that the manufacturer knew — or should have known — that its medications posed a risk of NAION, but failed to warn patients and physicians about that risk.
MDL 3163 Structure and Procedural Timeline
Federal lawsuits regarding semaglutide-associated vision loss have been centralized under the formal caption In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL No. 3163). Court dockets show rapid case growth from 29 to over 137 pending actions by mid-2026, with secondary trackers estimating total active matters between 146 and 200 by August.
| Proceeding Detail | Status / Milestone |
|---|---|
| Case Identifier | MDL No. 3163 (2:25-md-03163-KSM) |
| Presiding Judge | Judge Karen S. Marston, U.S. District Court, Eastern District of Pennsylvania |
| Primary Defendant | Novo Nordisk (maker of Ozempic, Wegovy, Rybelsus) |
| Key Procedural Events | Science Day held June 2, 2026; Case Management Order No. 12 entered July 2, 2026 |
| Discovery Deadline | Fact discovery scheduled to close in October 2026 |
| Settlement / Trial Status | No global settlement announced; no trials scheduled |
Following Science Day proceedings held in June 2026, Judge Marston issued Case Management Order No. 12 in July, steering the litigation toward a fact discovery cutoff in October 2026. Because these proceedings remain in the pretrial discovery phase, no trials have taken place, and no financial recovery funds have been established.
Contraindications & When to Consult a Doctor
The WHO advises patients to seek medical care immediately if they notice rapid changes in their eyesight.
Future Trajectory of the Litigation
As the October 2026 fact discovery deadline approaches in the Eastern District of Pennsylvania, the legal and medical communities await further court rulings. Until the judiciary evaluates the core scientific evidence through formal court trials, the legal claims remain unproven allegations.
References
- JAMA Ophthalmology: Evaluation of Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy Risk.
- Journal of the American Medical Association (JAMA): Comparative Ocular Safety Analysis of GLP-1 Receptor Agonists.
- World Health Organization (WHO): Pharmacovigilance Safety Communications on Semaglutide.
- U.S. District Court, Eastern District of Pennsylvania: MDL No. 3163 Docket Filings and Case Management Orders.
Disclaimer: This reporting is provided for informational and educational purposes only. This content does not constitute legal counsel or medical advice. Patients with specific health concerns should consult qualified licensed medical professionals.
